Bagsværd, Denmark, 12 May 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonCaroline Munk Esbjerg 2 Reason for the notification a)Position/statusClosely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO) b)Initial notification/AmendmentInitial notification 3 Details of the issuer a)NameNovo Nordisk A/S b)LEI549300DAQ1CVT6CXN342 4 Details of the transaction(s) a)Description of the financial instrument,
type of instrument,
Shares
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
Identification codeNovo Nordisk B DK0062498333 b)Nature of the transactionShares received as gift c)Price(s) and volume(s) Price(s)Volume(s) DKK 294.3050 d)Aggregated information
50 shares
DKK 14,715
e)Date of the transaction2026-05-07 f)Place of the transactionOutside a trading venue
1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonSofie Munk Esbjerg 2 Reason for the notification a)Position/statusClosely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO) b)Initial notification/AmendmentInitial notification 3 Details of the issuer a)NameNovo Nordisk A/S b)LEI549300DAQ1CVT6CXN342 4 Details of the transaction(s) a)Description of the financial instrument,
type of instrument,
Shares
Identification codeNovo Nordisk B DK0062498333 b)Nature of the transactionShares received as gift c)Price(s) and volume(s) Price(s)Volume(s) DKK 294.2550 d)Aggregated information
50 shares
DKK 14,712.50
e)Date of the transaction2026-05-07 f)Place of the transactionOutside a trading venue
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube
Contacts for further information
Company announcement No 31 / 2026
Attachment
